Clinical Trial Update: An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

View source ↗

Summary

Pfizer-sponsored observational study of Indian breast cancer patients receiving adjuvant exemestane (Aromasin) was terminated; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Status: TERMINATED | Results posted: 2013-11-19